Zepbound

Zepbound is the weight-loss-specific brand name for tirzepatide, the same active ingredient in Mounjaro. Approved by the FDA in November 2023, it’s the first dual GIP/GLP-1 receptor agonist specifically indicated for chronic weight management.

Key Differences from Mounjaro:

• Same molecule, different branding/packaging

• Approved specifically for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions

• Higher maximum dose (15mg vs Mounjaro’s 10mg for diabetes)

How It Works: Triple-Action Weight Loss

1. Brain (Appetite Control):

   • Reduces hunger signals by 40-60%

   • Decreases food cravings, especially for high-fat foods

2. Gut (Digestion):

   • Slows gastric emptying by 55-65%

   • Increases satiety hormones (PYY, GLP-1)

3. Fat Cells (Metabolism):

   • Improves insulin sensitivity

   • Promotes healthier fat distribution

Proven Results: Clinical Trial Data